News
Important Only
Air Products,Yara in talks to partner in ammonia project; shares fall
Shares of industrial gas company Air Products APD.N fall 7.2% to $241.95 APD in talks with Norwegian fertilizer producer Yara International YAR.OL to combine its low-emission ammonia projects in the U.S. and Saudi Arabia with Yara's world-scale ammonia networkYara will acquire ammonia productio...Reuters
Mon, Dec 8
LIVE MARKETS-Decennial pattern shows less bullish 2026
Stocks red; Dow off mostComm svcs down most among S&P sectors; Tech sole gainer STOXX 600 off ~0.1%Dollar edges up; gold slips; bitcoin turns lower, crude down ~1.5%U.S. 10-year Treasury yields rise to 4.18%Welcome to the home for real-time coverage of markets brought to you by Reuters reporters...Reuters
Mon, Dec 8
BUZZ US STOCKS ON THE MOVE-Tesla, Warner Bros Discovery, Netflix
The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8Wall Street's main indexes were mixed on Monday as investors treaded cautiously ahead of a widely expected Federal Reserve rate cut later this week in a meeting that is shaping up to be ...Reuters
Mon, Dec 8
Carvana, CRH hit record high on S&P 500 inclusion
Shares of Carvana CVNA.N rise 9% to $435.69, while CRH CRH.N adds 5.8% to $126.47, both hitting record highOnline used-car retailer CVNA and construction materials maker CRH set to join the S&P 500 .SPX, effective prior to the opening of trade on December 22Construction firm Comfort Systems USA ...Reuters
Mon, Dec 8
Truist initiates OneMain with 'buy'
Truist Securities initiates coverage of personal loan provider OneMain Holdings OMF.N with a "buy" rating and a $75 PT, which is a 16% upside from its last close Brokerage cites disciplined underwriting, strong capital returns and a potential catalyst from its industrial loan company bank ...Reuters
Mon, Dec 8
Incyte down after investors set high expectations for blood cancer therapy trial
Shares of drugmaker Incyte INCY.O fall 4% to $98.40INCY said on Sunday its experimental antibody therapy, INCA033989, showed significant reductions in spleen size and symptoms in patients with a type of rare blood cancer William Blair says "with Incyte shares up over 20% over the past two months...Reuters
Mon, Dec 8
US natgas companies drop on milder weather forecast
U.S. natgas futures NGc1 fell 5.7% to $4.987 per million British thermal unitNatgas prices fell on forecasts for less cold weather over the next two weeks than previously expected, near-record output, ample amounts of gas in storage and lower prices around the worldShares of natgas companies: Chenie...Reuters
Mon, Dec 8
LIVE MARKETS-Charging into the holidays: Consumer credit outstanding
Stocks turn red; Dow off mostTech biggest gainer among S&P sectors; Comm svcs down mostSTOXX 600 off ~0.1%Dollar inches higher; gold, crude slip; bitcoin reverses to be modestly lowerU.S. 10-year Treasury yields rise to 4.18%Welcome to the home for real-time coverage of markets brought to you by...Reuters
Mon, Dec 8
SOFTS-Robusta coffee hits 2-1/2 month low, London cocoa climbs
LONDON, Dec 8 (Reuters) - Robusta coffee prices fell to a 2-1/2 month low on Monday as the harvest in top grower Vietnam picked up after recent delays caused by storms and flooding. COFFEERobusta coffee LRCc2 fell 1.8% to $4,104 a metric ton by 1534 GMT after setting a 2-1/2 month low of $4...Reuters
Mon, Dec 8
Structure's obesity pill shows up to 11.3% weight loss in study, shares double
By Puyaan Singh Dec 8 (Reuters) - Structure Therapeutics GPCR.O said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company's shares more than 140% higher.Biotechs are vying for a piece of the lucrative obesity treatm...Reuters
Mon, Dec 8
Oppenheimer sets Street-high 8,100 S&P 500 target for 2026
Dec 8 (Reuters) - Oppenheimer Asset Management on Monday set a year-end 2026 target of 8,100 for the S&P 500 index .SPX, the most bullish forecast among major Wall Street brokerages, citing expectations of strong corporate earnings and continued resilience in the U.S. economy.The target implies ...Reuters
Mon, Dec 8
Citigroup raises Rockwell Automation's PT on demand for end markets
Citigroup raises Rockwell Automation's ROK.N PT to $466 from $439, maintains "buy" rating New PT an upside of 15.3% to stock's last close Citigroup sees solid demand across ROK's end markets and enhanced product offerings driving continued topline growth, despite lingerin...Reuters
Mon, Dec 8
EMERGING MARKETS-LatAm assets extend slide as politics test rate-fueled optimism
Currencies down 0.7%, stocks fall 0.4%Brazil stocks rebound after dropRegional politics in spotlightBy Niket Nishant Dec 8 (Reuters) - Latin American currencies extended their slide on Monday as investors fretted over political uncertainty and looked ahead to central bank decisions, while Brazil...Reuters
Mon, Dec 8
CANADA STOCKS-TSX muted as investors brace for important central bank decisions
By Avinash P Dec 8 (Reuters) - Canada's main stock index was subdued on Monday, with technology shares leading gains, ahead of crucial monetary policy decisions in the U.S. and Canada later this week.Toronto's S&P/TSX Composite Index .GSPTSE was flat at 31,296.10 points by 10:00 a.m....Reuters
Mon, Dec 8
Wave Life surges after positive data for its weight-loss drug
Shares of drug developer Wave Life Sciences WVE.O more than double to $15.4 premarketWVE says its experimental obesity drug helped cut deep belly fat and boost muscle mass in an early-stage studyThe drug, WVE-007, was tested in adults with an average starting body mass index of about 32Three months ...Reuters
Mon, Dec 8
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug
By Kamal ChoudhuryDec 8 (Reuters) - Mirum Pharmaceuticals MIRM.O said on Monday it will buy Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease.The deal will give the company worldwide rights to brelovitug, a monoclonal antibody ...Reuters
Mon, Dec 8
Ocular jumps on plans to fast-track FDA filing for eye disease drug
Shares of Ocular Therapeutix OCUL.O rise 27% to $15.91OCUL plans to submit a marketing application for its eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026Wet AMD is a leading cause o...Reuters
Mon, Dec 8
Dyne Therapeutics rises after positive data for its muscle wasting drug
Shares of drug developer Dyne Therapeutics DYN.O rise 16.2% to $23.62DYN's experimental drug zeleciment rostudirsen for the treatment of Duchenne muscular dystrophy (DMD) met the main goal in an early- to mid-stage trialIn a 32-patient study group that enrolled ambulant and non-ambulant males, t...Reuters
Mon, Dec 8
US STOCKS-U.S. stocks mixed as traders await Fed rate decision, Warner Bros jumps
Indexes: Dow down 0.26%, S&P 500 up 0.01%, Nasdaq up 0.31%Paramount Skydance launches a hostile bid for Warner BrothersConfluent jumps after report IBM nears $11 bln buyout dealBy Johann M Cherian and Pranav Kashyap Dec 8 (Reuters) - Wall Street's main indexes were mixed on Monday as ...Reuters
Mon, Dec 8
Canada's Transcontinental to sell its packaging unit in $1.61 billion deal
Dec 8 (Reuters) - Transcontinental TCLa.TO said on Monday it would sell its packaging unit to ProAmpac Holdings in a C$2.22 billion ($1.61 billion) deal, including debt, sending the Canadian firm's shares up 28%.The sale comes at a time when the packaging industry is grappling with high freight ...Reuters
Mon, Dec 8
